The fund invests directly in health treatments enabling Sipp holders to invest in a professionally managed venture fund.
The fund has quarterly closing dates beginnning in March and a minimum subscription of £10,000 with multiples of £1,000 thereafter.
Investments made by Longbow include software for the visualisation of medical images in three dimensions for use by radiologists and for clinical trials and devices to help women’s insight into their breast health.
Initial commission for advisers is 2.5 per cent of the amount subscribed plus trail commission of 0.5 per cent per annum over the lifetime of the investment.
Longbow partner Julian Hickman says: “Investing in alternative investments needs to a key part of any investment strategy, yet until now Sipp investors have had little chance to access a venture fund exclusively designed for Sipps.
“Innovation in healthcare is being driven by over-burdened health services as they seek better treatments for patients. Longbow’s Sipp fund will invest in this rising tide of creativity.”